We are live on ! Find out more
RCUS icon

Arcus Biosciences
RCUS

67 hedge funds and large institutions have $290M invested in Arcus Biosciences in 2018 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 27 increasing their positions, 13 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

108% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 13

100% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 10

25% more funds holding in top 10

Funds holding in top 10: 4 → 5 (+1)

18% more funds holding

Funds holding: 57 → 67 (+10)

10.09% more ownership

Funds ownership: 50.47% → 60.56% (+10%)

7% less capital invested

Capital invested by funds: $313M → $290M (-$22.9M)

Holders
67
Holders Change
+10
Holders Change %
+17.54%
% of All Funds
1.49%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.11%
New
20
Increased
27
Reduced
13
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
BI
BVF Inc
California
+$15.8M
2
BlackRock
BlackRock
New York
+$15M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$7.73M
4
State Street
State Street
Massachusetts
+$4.91M
5
Northern Trust
Northern Trust
Illinois
+$2.32M

Top Sellers

1
FCMI
Foresite Capital Management III
California
-$16.5M
2
EC
EcoR1 Capital
California
-$11.8M
3
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University
California
-$6.26M
4
PHS
PFM Health Sciences
California
-$5.87M
5
HIM
Hillhouse Investment Management
Cayman Islands
-$4.96M
Name Holding Trade Value Shares
Change 		Change in
Stake
TRCT
76
Tower Research Capital (TRC)
New York
– -$1K -56 Closed
LC
77
Lindbrook Capital
California
– +$584 +50 New
1 2 3
4

RCUS Hedge Fund Activity: Q4 2018 in Review

67 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q4 2018, worth a combined $290M — down 7.3% from $313M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new RCUS positions and 10 closed out — a net gain of 10 holders — while 27 added to existing stakes and 13 trimmed.

The largest buyer was BVF Inc, adding an estimated $15.8M. The largest seller was Foresite Capital Management III, cutting an estimated $16.5M.

  • 67 institutional investors held Arcus Biosciences (RCUS) as of Q4 2018, up from 57 in Q3 2018.
  • Funds reported $290M of Arcus Biosciences stock for Q4 2018, down 7.3% quarter-over-quarter.
  • 20 funds opened new Arcus Biosciences positions in Q4 2018 and 10 closed out, a net change of +10 holders.
  • The largest Arcus Biosciences buyer in Q4 2018 was BVF Inc, an estimated $15.8M added.
  • The largest Arcus Biosciences seller in Q4 2018 was Foresite Capital Management III, an estimated $16.5M sold.

Based on aggregated 13F filings for Q4 2018.